Shares of Dendreon (DNDN) are getting hammered in the post-trading session, despite reporting...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Shares of Dendreon (DNDN) are getting hammered in the post-trading session, despite reporting FQ4 earnings that largely beat estimates. The company forecasts only modest sales growth for Provenge, its blockbuster prostate cancer vaccine, over the next several quarters. Shares -22.5% AH.